
#### PhenoSense HIV Entry Assay


**Envelope Expression Vector: pHIVenv** 




HIV-1 Expression Vector: pHIVIuc∆U3



#### PhenoSense TMHIV: Cell Assay



### HIV Envelope Expression Strategies




# Co-Receptor Tropism Assay Interpretation

	R5 cells	R5 cells X4 cells	R5:X4
no drug	18	26,471	0
R5 inhibitor 🎬		19,258	in the street of
X4 inhibitor		32	
%inhib by R5 inhibitor	500g 10g 10g 10g 10g 10g 10g 10g 10g 10g	27	
%inhib by X4 inhibitor	* * *	100	

		28	%inhib by X4 inhibitor
		100	%inhib by R5 inhibitor
		42,295	X4 inhibitor
		66	R5 inhibitor
936	72	no drug 67,389	no drug
R5:X4	X 4	R5	
	17		

active RLU limit: 100 tropism ratio limit: 5



	R	95 X 4	R5.X4
no drug	43	42	
R5 inhibitor			
X4 inhibitor			
%inhib by R5 inhibitor			
%inhib by X4 inhibitor			

12,020 10,839 3,384

8,580


R5 inhibitor X4 inhibitor %inhib by R5 inhibitor %inhib by X4 inhibitor

14,982

no drug

FIG. 3A


# Co-Receptor Tropism Assay Interpretation



		<i>1</i> 43	%inhib by X4 inhibitor
		1000	%inhib by R5 inhibitor
		938'87	X4 inhibitor
		<b>3</b> 3	R5 inhibitor
936	778	60E'/L9	] bn drug
R5:X4	X 4	R5	
	21		

	٠		_
	CXCERA	ලලාල	DUAL or MIXED


active RLU limit: 100	tropism ratio limit: 5
ac	Ħ




3B	
<u>5</u>	
正	

	72	43	%inhib by X4 inhibitor
\(\frac{1}{2}\)	10	66	%inhib by R5 inhibitor
	3,384	8,580	X4 inhibitor
	10,839	111	R5 inhibitor
	12,020	14,982	no drug
R5:X4	X 4	R5	
	97		

Entry Inhibitor Susceptibility: Fusion Inhibitor



Reduced Susceptibility: Fusion Inhibitor



Entry Inhibitor Susceptibility: CCR5 Inhibitor




FIG. 5A

Drug: R5 Inhibitor Cell: CD4/CCR5

## Entry Inhibitor Susceptibility: CXCR4 Inhibitor





FIG. 5B

Drug: X4 Inhibitor Cell: CD4/CXCR4


TOOFFOFF. CEASTE


#### Enyelope Sequence Amplification




# of isolates 15 24 15 35	# of isolate 2 7 7 1 3
Co-Receptor Tropism X4 R5 X4/R5 Undefined	Envelope Subtype Clade A Clade B Clade C Clade C Clade C

Target Cell Receptor and Co-Receptor Expression







Rimsky, et al., at 20 at, 77 (2):506-953

## Figure X: Patient Virus v. Patient Antibody

				Plasm	Plasma (Antibody) Date	/) Date			
Virus Date	9/2/99	11/29/99	2/29/00	5/31/00	8/30/00	11/22/00	2/14/01	5/30/01	9/11/01
9/2/99	26	219	675	1403	2670	2089	2190	2363	2411
11/29/99	29	179	1024	2151	3733	3152	2808	2953	3086
2/29/00	27	35	78	358	1769	1939	2247	3112	4345
5/31/00	36	29	82	200	795	1078	1371	2208	3375
8/30/00	19	48	36	64	9/	166	556	937	1407
11/22/00	29	43	64	92	96	119	374	721	1234
2/14/01	42	99	61	152	117	134	122	289	526
5/30/01	41	99	82	84	85	113	78	107	296
9/11/01	42	62	56	62	85	77	55	61	92
Reference Virus									
NL43	17	138	294	926	1172	953	1584	1868	2143
JRCSL	24	37	35	09	87	26	105	152	209